Implementing BYOD Across Phase II and III Clinical Trials
About this webinar
The significant advantages for electronic patient-reported outcomes (ePRO) over paper records include improved compliance, data quality and patient experiences – these advantages will best be realized only when Bring Your Own Device (BYOD) for the collection of patient-reported outcomes is deployed across all trial phases. In practice, however, implementation of BYOD has been mostly isolated to Phase I and Phase IV trials.
Regardless, there are real opportunities now for bringing the promise of BYOD to Phase II and III. This webinar will review strategies and outcomes from a recent Phase III study supported by Clinical Ink, where BYOD was leveraged by 90 percent of its patient population for the collection of primary endpoint data, achieving a compliance rate well over 90 percent. The featured speaker in this webinar will also provide real-world examples for how other Phase II and III studies can also use BYOD for data collection.
Who should attend
- ePRO/ePRO Category/Data Managers
- Clinical Trial/Clinical Study Leads
- Therapeutic Strategy Leads
- Biometrics/Bio Stats Managers
- Clinical Operations Specialists
- Clinical Operations Directors/VPs
What you will learn
- Using BYOD for the collection of patient-reported outcomes
- Examples of strategies and outcomes of BYOD implementation based on a Phase III supported by Clinical Ink
- Implementing BYOD into Phase II and III trials
Featured Speakers
Gena Gough, MBA, PMP
Gena Gough is a project management professional with over 20 years of experience in project management applied to pharmaceutical clinical trials, electronic clinical outcomes assessments (eCOA), non-profit health care systems and academic medical centers. She serves as a subject matter expert for ePRO/eCOA, engagement services and technology standards, bringing more than a decade of ePRO/eCOA experience garnered across direct management of over 75 Phase II/III trials. Further, Gena represents Clinical Ink as a member representative in the ePRO Consortium.
Partner for this event
Clinical Ink
Clinical Ink is a global clinical trial technology company that is transforming the clinical trial experience. Founded in 2007, the Company’s proven and future-built eSource platform, which includes solutions for EDC replacement, eCOA, ePRO and more, accelerates time to value while delivering scientific results that matter. With offices in Winston-Salem, NC, and Philadelphia, PA, Clinical Ink is advancing the business model responsible for bringing new treatments to market. Visit clinicalink.com.
Related webinars
More from Clinical Ink.
Beyond Biometrics: Connecting Behavioral Profiles to Achieve the Right Kind of Weight Loss
COAs in Early-Stage Alzheimer’s Trials: How scientific strategy, eCOA & rater training align to protect endpoint & data quality
Enhancing Cardiometabolic Trials with Configurable eCOA and Digital Health Technologies
From Signals to Strategy: The Next Chapter of Digital Biomarkers
BYOD or Bust: Are Clinical Trials Ready for the Device Revolution?
Optimizing Patient Adherence in Clinical Trials: The Science of Risk Identification and Personalized Digital Interventions
Innovation Labs: Accelerating Innovation at the Intersection of Pharmaceutical Research and Digital Health
Electronic Data Capture Redefined: Challenging the Norm with eSource Innovation
Solving unmet needs in GLP1 cardiometabolic clinical trials: novel approaches to digital data capture and patient retention
New Approaches to Adherence and Prevention of Dropouts: The Digital Era of Patient Engagement
Solving Data Collection Challenges in Lupus Trials with the Electronic Lupus Assessment Suite
Empowerment Model: An eCOA Subscription Model for Maximum Efficiency, Cost Savings, and Control
